Usefulness of PCNA labeling index and p53 expression in determining prognosis in osteosarcoma

• Published in: Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 1997-03, Vol.2 (2), p.57-63
• Main Authors: Shiraishi, Hideo, Kotake, Toshiyuki
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Chemotherapy; Diseases of the osteoarticular system; Labeling; Medical sciences; osteosarcoma prognostic factors; p53 expression; PCNA labeling index; Proteins; Tumors of striated muscle and skeleton
• ISSN: 0949-2658; 1436-2023
• DOI: 10.1007/BF02489514

Immunohistochemical staining of osteosarcoma specimens was performed with anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody (PC10, Novocastra) and anti-p53 antibody (DO7, DAKO), using the streptavidinbiotin (SAE.) method. The average PCNA labeling index was 55.3% and all patients with a labeling index higher than 68% died of disease, p53 expression was 40.9% and the labeling index was 33.3% in patients who were continuously diseaseflee, but the index was 37.9% (average) in patients who died of disease; all patients with an index higher than 50% died of disease. However, in patients with metastasis, the p53 index was low in patients who survived after resection of the metastasis, suggesting that this profile may reflect the metastatic behavior of the tumor. We often perform preoperative chemotherapy for osteosarcoma and we consider that markers of the effect of chemotherapy are important in predicting survival. It seems that an increase in the PCNA labeling index and an increase in the p53 labeling index or in p53 expression after chemotherapy indicates a good prognosis.